Enliven Therapeutics, Inc. - Common Stock (ELVN)

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Ortex data shows short interest in Enliven Therapeutics had hovered between 24% and 29% since October 2023.

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant sales potential for Enliven's therapies.

ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising safety and efficacy data.

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.

Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho bullish with Buy rating, $34 price target. ELVN's trading value suggests conservative estimation compared to CML market potential.

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.

Stocks are scattered midday Tuesday, as investors digest the semiconductor sector's pullback that's being led by the shares of Nvidia.

U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.

ELVN stock results show that Enliven Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.